Pharmacologic targeting or genetic downregulation of BCL6 results in the death of DLBCL, BL, and FL cell lines or primary human patient specimens within 48‐72 hours.86, 92, 93, 94 It was noted previously that GC B cells manifest many of the biological hallmarks of tumor cells, many of which are driven by BCL6. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.